Analyst Scott Fidel of Goldman Sachs maintained a Buy rating on UnitedHealth, boosting the price target to $406.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Scott Fidel has given his Buy rating due to a combination of factors including UnitedHealth’s strong financial performance and strategic adjustments. The company reported adjusted earnings per share (EPS) for the third quarter of 2025 that surpassed both Goldman Sachs’ and consensus estimates, indicating robust financial health.
Additionally, UnitedHealth improved its full-year EPS guidance, reflecting confidence in its future earnings potential. Despite some pressure in the Optum Health segment due to Medicare funding cuts and increased utilization, the overall performance, including a favorable medical cost ratio, supports a positive outlook for the company’s stock.
In another report released today, Mizuho Securities also reiterated a Buy rating on the stock with a $430.00 price target.